Biogen Signs Preclinical Gene Editing Deal with Sangamo

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 3 (Table of Contents)

Published: 4 Mar-2020

DOI: 10.3833/pdr.v2020.i3.2516     ISSN: 1756-7874

Section: Research & Development



Continuing to bolster its early-stage pipeline, Biogen has partnered with Sangamo Therapeutics to develop gene editing treatments for neurology indications using the latter’s zinc finger nuclease technology...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details